Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy

Journal of the American College of Cardiology

Volumn 43, Issue 11, 2004, Pages 2116-2123

  Yasunari, Kenichi ^a   Maeda, Kensaku ^a   Watanabe, Takanori ^a   Nakamura, Munehiro ^a   Yoshikawa, Junichi ^a   Asada, Akira ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

angiotensin II; angiotensin receptor blocker; ARB; ATII; blood pressure; BP; C reactive protein; carboxydichlorofluorescein diacetate bis acetoxymethyl ester; CDCFH bis AM ester; CRP; IL; interleukin; left ventricular; left ventricular hypertrophy; LV; LVH; LVMI

Indexed keywords

ALDOSTERONE; AMLODIPINE; RENIN; VALSARTAN;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MULTIPLE REGRESSION; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGRESSION ANALYSIS; RISK FACTOR;

AMLODIPINE; ANTIHYPERTENSIVE AGENTS; CROSS-SECTIONAL STUDIES; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; FEMALE; FLOW CYTOMETRY; HEART VENTRICLES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; MONOCYTES; PROSPECTIVE STUDIES; REACTIVE OXYGEN SPECIES; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 2542475889     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2003.12.051     Document Type: Article

References (26)

1. Levy D., Garrison R.J., Savage D.D., Kannel W.B., Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 322:1990;1561-1566
2. Koren M.J., Devereux R.B., Casale P.N., Savage D.D., Laragh J.H. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 114:1991;345-352
3. Schunkert H., Hense H.W., Holmer S.R., et al. Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N Engl J Med. 330:1994;1634-1638
4. Tarazi R.C., Sen S., Saragoca M., Khairallah P. The multifactorial role of catecholamines in hypertensive cardiac hypertrophy. Eur Heart J. 3:1982;103-110
5. Morgan H.E., Baker K.M. Cardiac hypertrophy Mechanical, neural, and endocrine dependence. Circulation. 83:1991;13-25
6. Lindpaintner K., Ganten D. The cardiac renin-angiotensin system An appraisal of present experimental and clinical evidence. Circ Res. 68:1991;905-921
7. Schmieder R.E., Langenfeld M.R., Friedrich A., Schobel H.P., Gatzka C.D., Weihprecht H. Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension. Circulation. 94:1996;1304-1309
8. Thürmann P.A., Kenedi P., Schmidt A., Schmidt A., Harder S., Rietbrock N. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation. 98:1998;2037-2042
9. Dorffel Y., Latsch C., Stuhlmuller B., Schreiber S., Scholze S. Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension. 34:1999;113-117
10. Chul Sung K., Suh J.Y., Kim B.S., et al. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens. 16:2003;429-433
11. Alexander R.W. The Jeremiah Metzger Lecture. Pathogenesis of atherosclerosis Redox as a unifying mechanism. Trans Am Clin Climatol Assoc. 114:2003;273-304
12. Yasunari K., Maeda K., Nakamura M., Yoshikawa J. Oxidative stress in leukocytes is a possible link between blood pressure, blood glucose, and C-reactive protein. Hypertension. 39:2002;777-780
13. Li J.J., Chen X.J. Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein and lipopolysaccharide. Coron Artery Dis. 14:2003;329-334
14. Hirota H., Yoshida K., Kishimoto T., et al. Continuous activation of gp 130, signal-transducing receptor component for interleukin-6-related cytokines, cause myocardial hypertrophy in mice. Proc Natl Acad Sci USA. 92:1995;4862-4866
15. Viberti G., Wheeldon N.M. for the MARVAL Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus A blood pressure independent effect. Circulation. 106:2002;672-678
16. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) A randomised trial against atenolol. Lancet. 359:2002;995-1003
17. Devereux R.B., Alonso D.R., Lutas E.M., et al. Echocardiographic assessment of left ventricular hypertrophy Comparison to necropsy findings. Am J Cardiol. 57:1986;450-458
18. Yasunari K., Kohno M., Kano H., Yokokawa K., Minami M., Yoshikawa J. Antioxidants improve impaired insulin-mediated glucose uptake and prevent migration and proliferation of cultured rabbit coronary smooth muscle cells induced by high glucose. Circulation. 99:1999;1370-1378
19. Yasunari K., Kohno M., Kano H., Minami M., Yoshikawa J. Dopamine as a novel antioxidative agent for rat vascular smooth muscle cells through dopamine D(1)-like receptors. Circulation. 101:2000;2302-2308
20. Sahn D.J., DeMaria A., Kisslo J., Weyma A. Recommendations regarding quantitation in M-mode echocardiography Results of a survey of echocardiographic measurements. Circulation. 58:1978;1072-1083
21. Yanagitani Y., Rakugi H., Okamura A., et al. Angiotensin II type 1 receptor-mediated peroxide production in human macrophages. Hypertension. 33:1999;335-339
22. Cheng Z.J., Vaskonen T., Tikkanen I., et al. Endothelial dysfunction and salt-sensitive hypertension in spontaneously diabetic Goto-Kakizaki rats. Hypertension. 37:2001;433-439
23. Peeters A.C., Netea M.G., Kullberg B.J., Thien T., van der Meer J.W. The effect of renin-angiotensin system inhibitors on pro- and anti-inflammatory cytokine production. Immunology. 94:1998;376-379
24. Prasad A., Koh K.K., Schenke W.H., et al. Role of angiotensin II type 1 receptor in the regulation of cellular adhesion molecules in atherosclerosis. Am Heart J. 142:2001;248-253
25. Koh K.K., Ahn J.Y., Han S.H., et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol. 42:2003;905-910
26. Kojima M., Shiojima I., Yamazaki T., et al. Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signalling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro. Circulation. 89:1994;2204-2211